title: [Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
authors.forename: Seiji
authors.initials: S
authors.lastname: Yano
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D000077547:Crizotinib; D055808:Drug Discovery; D004502:Education, Medical, Continuing; D000069347:Erlotinib Hydrochloride; D005047:Etoposide / Q000008:administration & dosage; D000077156:Gefitinib; D005971:Glutamates / Q000008:administration & dosage; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy; D000068437:Pemetrexed; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005971:Glutamates; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011799:Quinazolines; D000068437:Pemetrexed; D000068258:Bevacizumab; D000077547:Crizotinib; D006147:Guanine; D005047:Etoposide; D000077146:Irinotecan; D000069347:Erlotinib Hydrochloride; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D002945:Cisplatin; D000077156:Gefitinib; D002166:Camptothecin